Resverlogix Corp. (RVXCF)

[growacet]

Sample Size Recalculation Analysis....

Early in 2018 there was the thought that the BETonMACE trial might need to increase enrollment in order to optimize results. I think its a dead issue at this point though.

I attended an investor presentation in Toronto back in early May and had a brief one on one with the CEO Don McCaffrey. During his public presentation he stated that the trial is "properly powered" at 2,400 patients....

Personally and in my opinion I think another DSMB report would serve the same purposes....if a SSRA would be done its the DSMB that would make the recommendation to do it.

https://www.resverlogix.com/investors/news.html?article=593